A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints

被引:24
|
作者
Sugimoto, Tomoyuki [1 ]
Sozu, Takashi [2 ]
Hamasaki, Toshimitsu [3 ]
机构
[1] Hirosaki Univ, Grad Sch Sci & Technol, Dept Math Sci, Hirosaki, Aomori 0368561, Japan
[2] Kyoto Univ, Sch Publ Hlth, Dept Biostat, Sakyo Ku, Kyoto 6068501, Japan
[3] Osaka Univ, Grad Sch Med, Dept Biomed Stat, Suita, Osaka 5650871, Japan
关键词
correlated endpoints; multivariate normal; intersection-union test; two-arm design; superiority; power; DOUBLE-BLIND; DONEPEZIL;
D O I
10.1002/pst.505
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The clinical efficacy of a new treatment may often be better evaluated by two or more co-primary endpoints. Recently, in pharmaceutical drug development, there has been increasing discussion regarding establishing statistically significant favorable results on more than one endpoint in comparisons between treatments, which is referred to as a problem of multiple co-primary endpoints. Several methods have been proposed for calculating the sample size required to design a trial with multiple co-primary correlated endpoints. However, because these methods require users to have considerable mathematical sophistication and knowledge of programming techniques, their application and spread may be restricted in practice. To improve the convenience of these methods, in this paper, we provide a useful formula with accompanying numerical tables for sample size calculations to design clinical trials with two treatments, where the efficacy of a new treatment is demonstrated on continuous co-primary endpoints. In addition, we provide some examples to illustrate the sample size calculations made using the formula. Using the formula and the tables, which can be read according to the patterns of correlations and effect size ratios expected in multiple co-primary endpoints, makes it convenient to evaluate the required sample size promptly. Copyright (c) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:118 / 128
页数:11
相关论文
共 50 条
  • [1] Sample size determination in clinical trials with multiple co-primary binary endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    [J]. STATISTICS IN MEDICINE, 2010, 29 (21) : 2169 - 2179
  • [2] Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables
    Wu, Beilei
    de Leon, Alexander R.
    [J]. BIOMETRICAL JOURNAL, 2013, 55 (05) : 807 - 812
  • [3] Sample Size Determination in Superiority Clinical Trials with Multiple Co-Primary Correlated Endpoints
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (04) : 650 - 668
  • [4] Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    [J]. BIOMETRICAL JOURNAL, 2012, 54 (05) : 716 - 729
  • [5] Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints
    Huang, Wong-Shian
    Hung, Hui-Nien
    Hamasaki, Toshimitsu
    Hsiao, Chin-Fu
    [J]. PLOS ONE, 2017, 12 (06):
  • [6] "Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables" Reply
    Sozu, Takashi
    Sugimoto, Tomoyuki
    Hamasaki, Toshimitsu
    [J]. BIOMETRICAL JOURNAL, 2013, 55 (05) : 813 - 813
  • [7] Sample size calculation in clinical trials with two co-primary endpoints including overdispersed count and continuous outcomes
    Homma, Gosuke
    Yoshida, Takuma
    [J]. PHARMACEUTICAL STATISTICS, 2024, 23 (01) : 46 - 59
  • [8] Sample size determination in group-sequential clinical trials with two co-primary endpoints
    Asakura, Koko
    Hamasaki, Toshimitsu
    Sugimoto, Tomoyuki
    Hayashi, Kenichi
    Evans, Scott R.
    Sozu, Takashi
    [J]. STATISTICS IN MEDICINE, 2014, 33 (17) : 2897 - 2913
  • [9] Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints
    Yang, Jiaying
    Li, Jingxin
    Wang, Shiyuan
    Luo, Li
    Liu, Pei
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (01) : 256 - 263
  • [10] Evaluating Co-primary Endpoints Collectively in Clinical Trials
    Li, Qian H.
    [J]. BIOMETRICAL JOURNAL, 2009, 51 (01) : 137 - 145